Last €49.44 EUR
Change Today +0.195 / 0.40%
Volume 0.0
DSM2 On Other Exchanges
EN Amsterdam
As of 11:22 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

koninklijke dsm nv (DSM2) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/13 - €60.08
52 Week Low
02/27/14 - €45.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KONINKLIJKE DSM NV (DSM2)

Related News

No related news articles were found.

koninklijke dsm nv (DSM2) Related Businessweek News

View More BusinessWeek News

koninklijke dsm nv (DSM2) Details

Koninklijke DSM N.V. operates as a life sciences and materials sciences company worldwide. The company operates in five segments: Nutrition, Pharma, Performance Materials, Polymer Intermediates, and Innovation Center. It manufactures food enzymes, cultures, savory ingredients, and other specialties, as well as nutritional products, such as vitamins, carotenoids, eubiotics, feed enzymes, premixes, nutritional lipids, and cultures for the food and beverage, feed, personal care, dietary supplements, and pharmaceutical industries. The company also provides custom manufacturing and development services to the pharmaceutical, biopharmaceutical, and agrochemical industries; and beta-lactam active pharmaceutical ingredients, such as semi-synthetic penicillins and semi-synthetic cephalosporins, as well as nystatin. In addition, it offers engineering thermoplastic solutions; Dyneema, a strong fiber; and resins solutions for paints and coatings, composite materials, and optical fiber coatings. Further, the company produces caprolactam and acrylonitrile that are raw materials for synthetic fibers and plastics; and other products, including ammonium sulfate, sodium cyanide, cyclohexanone, and diaminobutane. Additionally, it develops materials-based solutions comprising coatings, drug delivery platforms, and a range of biomedical materials for medical device and biopharmaceutical industries; creates solutions for bioconversion of feedstocks for the production of bio-energy, such as cellulosic biofuels, as well as bio-based chemicals and materials; and provides smart coatings and surface technologies to the solar industry. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

21,857 Employees
Last Reported Date: 02/26/14
Founded in 1902

koninklijke dsm nv (DSM2) Top Compensated Officers

Chairman of Managing Board, Chief Executive O...
Total Annual Compensation: €1.4M
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €902.0K
Member of The Managing Board
Total Annual Compensation: €954.0K
Member of Managing Board
Total Annual Compensation: €887.0K
Member of The Managing Board
Total Annual Compensation: €268.0K
Compensation as of Fiscal Year 2013.

koninklijke dsm nv (DSM2) Key Developments

Royal DSM Reveals Negotiations To Buy Aland

Koninklijke DSM N.V. (ENXTAM:DSM) (Royal DSM) is in talks with Aland (Jiangsu) Nutraceutical Co., Ltd. Koninklijke unveiled its exclusive negotiations over a possible deal to buy Aland Nutraceutical.

DSM In Talks To Buy Aland

Koninklijke DSM N.V. (ENXTAM:DSM) is in advanced talks to buy Aland (Jiangsu) Nutraceutical Co., Ltd. DSM is said to be close to reaching a deal to acquire Aland. An industry source said DSM wants to expand its presence in the fast-growing market in a bid to drive down its manufacturing costs.

DSM Partners with Sayan Orthopaedics Ltd. for the Use of Dyneema Purity Fiber in Innovative Device for Trauma Treatment

DSM announced a partnership with Sayan Orthopaedics Ltd. Sayan will use DSM's Dyneema Purity(R) fiber in a trauma treatment device, having a combination of different types of Dyneema Purity(R) ultra-high-molecular-weight polyethylene (UHMWPE) fiber only. Sayan's trauma device will use an UHMWPE braid made out of DSM's Dyneema Purity(R) fibers. With a fiber 15 times stronger than steel, the braid will be able to withstand high levels of force due to its strength and stiffness. Furthermore, the braid's small diameter, high pliability and increased flexibility in combination with the device design, allows for easier adjustments during implantation. In addition to this the braid conforms to the shape of the bone, increasing the contact surface and lowering contact pressure. Patients are expected to experience increased comfort due to softness of Dyneema Purity(R) fibers. The absence of sharp edges may be expected to minimize cutting into bone or soft tissue, which sometimes occurs with steel devices. Tissue inflammation and irritation are also minimized due to the fiber's biocompatibility and chemically inert properties. Additionally, using Dyneema Purity(R) overcomes complications associated with metal allergies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSM2:GR €49.44 EUR +0.195

DSM2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agrium Inc C$102.56 CAD -0.85
Grupo Bimbo SAB de CV $35.97 MXN +0.46
Kerry Group PLC €54.70 EUR -0.71
Merck KGaA €115.25 EUR +0.45
Solvay SA €112.75 EUR +0.50
View Industry Companies

Industry Analysis


Industry Average

Valuation DSM2 Industry Range
Price/Earnings 34.2x
Price/Sales 1.0x
Price/Book 1.5x
Price/Cash Flow 33.2x
TEV/Sales 0.6x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE DSM NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at